Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma
Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection
pump combined DP scheme for first-line advanced lung squamous carcinoma and maintenance
treatment., and explore the predicted biomarkers.
Phase:
Phase 4
Details
Lead Sponsor:
Nanjing NingQi Medicine Science and Technology Co., Ltd.